Literature DB >> 33199209

PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.

Christopher D Nishimura1, Marc C Pulanco1, Wei Cui2, Liming Lu3, Xingxing Zang4.   

Abstract

Immune checkpoints negatively regulate immune cell responses. Programmed cell death protein 1:programmed death ligand 1 (PD-1:PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4):B7-1 are among the most important immune checkpoint pathways, and are key targets for immunotherapies that seek to modulate the balance between stimulatory and inhibitory signals to lead to favorable therapeutic outcomes. The current dogma of these two immune checkpoint pathways has regarded them as independent with no interactions. However, the newly characterized PD-L1:B7-1 ligand-ligand cis-interaction and its ability to bind CTLA-4 and CD28, but not PD-1, suggests that these pathways have significant crosstalk. Here, we propose that the PD-L1:B7-1 cis-interaction brings novel mechanistic understanding of these pathways, new insights into mechanisms of current immunotherapies, and fresh ideas to develop better treatments in a variety of therapeutic settings.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  B7-1; CD28; CTLA-4; PD-1; PD-L1; cis-interaction; immunotherapy

Year:  2020        PMID: 33199209      PMCID: PMC7914151          DOI: 10.1016/j.molmed.2020.10.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  76 in total

Review 1.  Effector mechanisms of rejection.

Authors:  Aurélie Moreau; Emilie Varey; Ignacio Anegon; Maria-Cristina Cuturi
Journal:  Cold Spring Harb Perspect Med       Date:  2013-11-01       Impact factor: 6.915

2.  Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion.

Authors:  Bertram Bengsch; Andy L Johnson; Makoto Kurachi; Pamela M Odorizzi; Kristen E Pauken; John Attanasio; Erietta Stelekati; Laura M McLane; Michael A Paley; Greg M Delgoffe; E John Wherry
Journal:  Immunity       Date:  2016-08-02       Impact factor: 31.745

3.  B7, a B-cell-restricted antigen that identifies preactivated B cells.

Authors:  A S Freedman; G Freeman; J C Horowitz; J Daley; L M Nadler
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

4.  Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.

Authors:  Udupi A Ramagopal; Weifeng Liu; Sarah C Garrett-Thomson; Jeffrey B Bonanno; Qingrong Yan; Mohan Srinivasan; Susan C Wong; Alasdair Bell; Shilpa Mankikar; Vangipuram S Rangan; Shrikant Deshpande; Alan J Korman; Steven C Almo
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-08       Impact factor: 11.205

5.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

6.  CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.

Authors:  Chrysoula I Liakou; Ashish Kamat; Derek Ng Tang; Hong Chen; Jingjing Sun; Patricia Troncoso; Christopher Logothetis; Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

7.  Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.

Authors:  Edward Cha; Mark Klinger; Yafei Hou; Craig Cummings; Antoni Ribas; Malek Faham; Lawrence Fong
Journal:  Sci Transl Med       Date:  2014-05-28       Impact factor: 17.956

8.  Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.

Authors:  Philip J Mease; Alice B Gottlieb; Désirée van der Heijde; Oliver FitzGerald; Alyssa Johnsen; Marleen Nys; Subhashis Banerjee; Dafna D Gladman
Journal:  Ann Rheum Dis       Date:  2017-05-04       Impact factor: 19.103

9.  Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells.

Authors:  M Fehlings; Y Simoni; H L Penny; E Becht; C Y Loh; M M Gubin; J P Ward; S C Wong; R D Schreiber; E W Newell
Journal:  Nat Commun       Date:  2017-09-15       Impact factor: 14.919

10.  PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.

Authors:  Yunlong Zhao; Calvin K Lee; Chia-Hao Lin; Rodrigo B Gassen; Xiaozheng Xu; Zhe Huang; Changchun Xiao; Cristina Bonorino; Li-Fan Lu; Jack D Bui; Enfu Hui
Journal:  Immunity       Date:  2019-11-19       Impact factor: 31.745

View more
  5 in total

Review 1.  Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy.

Authors:  Tao Wang; Desirée Denman; Silvia M Bacot; Gerald M Feldman
Journal:  Biomedicines       Date:  2022-05-20

2.  Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.

Authors:  Yanhao Liu; Yan Xu; Xi Cheng; Yaru Lin; Shu Jiang; Haiming Yu; Zhen Zhang; Linlin Lu; Xiaotao Zhang
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

3.  HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer.

Authors:  Yizhou Zhang; Hanrong Li; Chao Lv; Baokang Wu; Yang Yu; Chongli Zhong; Qi Lang; Zhiyun Liang; Yang Li; Yu Shi; Jian Zhang; Feng Xu; Yu Tian
Journal:  Int J Oncol       Date:  2022-08-03       Impact factor: 5.884

4.  Evolving Understanding of T-cell Cosignaling Pathways.

Authors:  Ya-Long Yang; Yuan-Yuan Li; Feng-Hua Xu
Journal:  Transplantation       Date:  2022-07-22       Impact factor: 5.385

5.  Topological and Structural Plasticity of the Single Ig Fold and the Double Ig Fold Present in CD19.

Authors:  Philippe Youkharibache
Journal:  Biomolecules       Date:  2021-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.